1. Home
  2. NVNI vs CERS Comparison

NVNI vs CERS Comparison

Compare NVNI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVNI
  • CERS
  • Stock Information
  • Founded
  • NVNI 2019
  • CERS 1991
  • Country
  • NVNI Brazil
  • CERS United States
  • Employees
  • NVNI N/A
  • CERS N/A
  • Industry
  • NVNI
  • CERS EDP Services
  • Sector
  • NVNI
  • CERS Technology
  • Exchange
  • NVNI Nasdaq
  • CERS Nasdaq
  • Market Cap
  • NVNI 245.6M
  • CERS 286.0M
  • IPO Year
  • NVNI N/A
  • CERS 1997
  • Fundamental
  • Price
  • NVNI $1.57
  • CERS $1.79
  • Analyst Decision
  • NVNI
  • CERS Buy
  • Analyst Count
  • NVNI 0
  • CERS 3
  • Target Price
  • NVNI N/A
  • CERS $3.17
  • AVG Volume (30 Days)
  • NVNI 5.9M
  • CERS 1.5M
  • Earning Date
  • NVNI 02-07-2025
  • CERS 03-04-2025
  • Dividend Yield
  • NVNI N/A
  • CERS N/A
  • EPS Growth
  • NVNI N/A
  • CERS N/A
  • EPS
  • NVNI N/A
  • CERS N/A
  • Revenue
  • NVNI $23,558,620.00
  • CERS $176,229,000.00
  • Revenue This Year
  • NVNI $25.91
  • CERS $21.42
  • Revenue Next Year
  • NVNI $17.52
  • CERS $11.12
  • P/E Ratio
  • NVNI N/A
  • CERS N/A
  • Revenue Growth
  • NVNI 38.59
  • CERS 14.71
  • 52 Week Low
  • NVNI $0.33
  • CERS $1.38
  • 52 Week High
  • NVNI $12.19
  • CERS $2.59
  • Technical
  • Relative Strength Index (RSI)
  • NVNI 45.29
  • CERS 57.04
  • Support Level
  • NVNI $1.26
  • CERS $1.74
  • Resistance Level
  • NVNI $1.75
  • CERS $1.89
  • Average True Range (ATR)
  • NVNI 0.54
  • CERS 0.11
  • MACD
  • NVNI -0.28
  • CERS 0.03
  • Stochastic Oscillator
  • NVNI 8.88
  • CERS 74.36

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: